{"protocolSection":{"identificationModule":{"nctId":"NCT00896454","orgStudyIdInfo":{"id":"20070315"},"organization":{"fullName":"Amgen","class":"INDUSTRY"},"briefTitle":"Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium","officialTitle":"A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates"},"statusModule":{"statusVerifiedDate":"2018-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-11-16","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2012-09-13","type":"ACTUAL"},"completionDateStruct":{"date":"2013-08-21","type":"ACTUAL"},"studyFirstSubmitDate":"2009-05-07","studyFirstSubmitQcDate":"2009-05-07","studyFirstPostDateStruct":{"date":"2009-05-11","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-12-19","resultsFirstSubmitQcDate":"2014-12-19","resultsFirstPostDateStruct":{"date":"2015-01-01","type":"ESTIMATED"},"dispFirstSubmitDate":"2014-05-08","dispFirstSubmitQcDate":"2014-05-08","dispFirstPostDateStruct":{"date":"2014-05-23","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-09-20","lastUpdatePostDateStruct":{"date":"2018-10-17","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Amgen","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to determine the potential of denosumab to treat Hypercalcemia of Malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates by lowering corrected serum calcium \\</= 11.5 mg/dL (2.9 millimoles /L) by day 10."},"conditionsModule":{"conditions":["Breast Cancer","Hypercalcemia of Malignancy","Colon Cancer","Endocrine Cancer","Head and Neck Cancer","Kidney Cancer","Lung Cancer","Lymphoma","Metastatic Cancer","Multiple Myeloma","Parathyroid Neoplasms","Renal Cancer","Thyroid Cancer","Hodgkin's Lymphoma","Non-Hodgkin's Lymphoma","Non-Small Cell Lung Cancer"],"keywords":["hypercalcemia","calcium","bisphosphonates","denosumab","amgen","malignancy","20070315","HMC","oncology","hematology"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":33,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"denosumab","type":"EXPERIMENTAL","description":"Eligible subjects will receive denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.","interventionNames":["Drug: denosumab"]}],"interventions":[{"type":"DRUG","name":"denosumab","description":"120 mg subcutaneously (SC) every 4 weeks with a loading dose of 120 mg SC on study days 8 and 15.","armGroupLabels":["denosumab"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With a Response Within 10 Days of First Dose of Denosumab","description":"Response is defined as corrected serum calcium (CSC) ≤ 11.5 mg/dL, within 10 days after the first dose of denosumab. For all CSC values, if albumin was \\< 4 g/dL, the following formula was used to calculate CSC: CSC = Total serum calcium \\[mg/dL\\] + (0.8 x (4 - serum albumin \\[g/dL\\]))","timeFrame":"10 days"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With a Response by Visit","description":"Response is defined as corrected serum calcium (CSC) ≤ 11.5 mg/dL, within 10 days after the first dose of denosumab. For all CSC values, if albumin was \\< 4 g/dL, the following formula was used to calculate CSC: CSC = Total serum calcium \\[mg/dL\\] + (0.8 x (4 - serum albumin \\[g/dL\\]))","timeFrame":"Days 2, 4, 8, 10, 15, 19, 23, 29, 36, 43, 50 and 57"},{"measure":"Percentage of Participants With a Complete Response by Visit","description":"Response is defined as corrected serum calcium (CSC) ≤ 10.8 mg/dL (2.7 mmol/L). For all CSC values, if albumin was \\< 4 g/dL, the following formula was used to calculate CSC: CSC = Total serum calcium \\[mg/dL\\] + (0.8 x (4 - serum albumin \\[g/dL\\])).","timeFrame":"Days 2, 4, 8, 10, 15, 19, 23, 29, 36, 43, 50 and 57"},{"measure":"Time to Response","description":"Time to Response was defined as the time period from study Day 1 to the first time post-baseline corrected serum calcium (CSC) ≤ 11.5 mg/dL. Participants were censored on the last CSC assessment day if no response was observed. If there was no post-baseline CSC assessment, time to response was censored on study Day 1.\n\nTime to response was analyzed using Kaplan-Meier methods.","timeFrame":"From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months."},{"measure":"Time to Complete Response","description":"Time to complete response was defined as the time period from study Day 1 to the first time post-baseline corrected serum calcium (CSC) was ≤ 10.8 mg/dL (2.7 mmol/L). Participants were censored on the last CSC assessment day if no complete response was observed. If there was no post-baseline CSC assessment, time to complete response was censored on study Day 1. Time to complete response was analyzed using Kaplan-Meier methods.","timeFrame":"From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months."},{"measure":"Duration of Response","description":"Duration of response is defined as the number of days from the first day of corrected serum calcium ≤ 11.5 mg/dL (2.9 millimoles/L) to the last day of corrected serum calcium ≤ 11.5 mg/dL. Participants were censored on the last CSC assessment day if their CSC level never reached \\> 11.5 mg/dL after the first response. If a participant had no CSC assessment after the first response, duration of response was set to zero and censored. Duration of response was summarized for participants who achieved a response using the Kaplan-Meier method.","timeFrame":"From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months."},{"measure":"Duration of Complete Response","description":"Duration of complete response is defined as the number of days from the first day of of corrected serum calcium ≤ 10.8 mg/dL (2.7 millimoles/L) to the last day of corrected serum calcium ≤ 10.8 mg/dL. Participants were censored on the last CSC assessment day if their CSC level never reached \\> 10.8 mg/dL after the complete response. If a participant had no CSC assessment after the complete response, duration of complete response was set to zero and censored. Duration of complete response was summarized for participants who achieved a complete response using the Kaplan-Meier method.","timeFrame":"From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months."},{"measure":"Time to Relapse/Nonresponse of Hypercalcemia of Malignancy","description":"Time to relapse/nonresponse was defined as the number of days from study Day 1 until the last day of CSC ≤ 11.5 mg/dL for all particiipants with relapse after the first response. Participants were censored on the last CSC assessment day if their CSC level never reached \\> 11.5 mg/dL after first response. For participants who never achieved response, time to relapse/nonresponse was set to zero. Otherwise, if there was no post-baseline CSC assessment, time to relapse/nonresponse was censored on study Day 1. Time to relapse/nonresponse was estimated using the Kaplan-Meier method.","timeFrame":"From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months."},{"measure":"Change From Baseline in Corrected Serum Calcium","timeFrame":"Baseline and Days 2, 4, 8, 10, 15, 19, 23, 29, 36, 43, 50 and 57"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Hypercalcemia of Malignancy (HCM) as defined as documented histologically or cytologically confirmed cancer and a corrected serum calcium (CSC) \\> 12.5 mg/dL (3.1 millimoles /L) at screening by local laboratory\n* Last IV bisphosphonate treatment must be \\>/= to 7 days and \\</= to 30 days before the screening corrected serum calcium\n* Adults (\\>/=18 years)\n* Adequate organ function as defined by the following criteria:\n* serum aspartate aminotransferase (AST) \\</= 5 x upper limit of normal (ULN)\n* serum alanine aminotransferase (ALT) \\</= 5 x upper limit of normal\n* serum total bilirubin \\</= 2 x upper limit of normal\n\nExclusion Criteria:\n\n* Evidence of benign hyperparathyroidism, hyperthyroidism, adrenal insufficiency, vitamin D intoxication, milk alkali syndrome, sarcoidosis, or other granulomatous disease\n* Receiving dialysis for renal failure\n* Treatment with thiazides, calcitonin, mithramycin, or gallium nitrate within their window of expected therapeutic effect (as determined by the physician) prior to the date of the screening CSC\n* Treatment with cinacalcet within 4 weeks prior to the date of the screening CSC\n* Thirty days or less since receiving an investigational product (other than denosumab) or device (ie, does not have marketing authorization; thalidomide use is allowed) in another clinical study\n* Known sensitivity to any of the products to be administered during the study (eg, mammalian derived products)\n* Female subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment\n* Female subject of childbearing potential is not willing to use 2 highly effective methods of contraception during treatment and for 7 months after the end of treatment\n* Subject will not be available for follow-up assessment.\n* Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"MD","affiliation":"Amgen","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Research Site","city":"Encinitas","state":"California","zip":"92024","country":"United States","geoPoint":{"lat":33.03699,"lon":-117.29198}},{"facility":"Research Site","city":"New Haven","state":"Connecticut","zip":"06520","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Research Site","city":"Salisbury","state":"Maryland","zip":"21801","country":"United States","geoPoint":{"lat":38.36067,"lon":-75.59937}},{"facility":"Research Site","city":"Dearborn","state":"Michigan","zip":"48124","country":"United States","geoPoint":{"lat":42.32226,"lon":-83.17631}},{"facility":"Research Site","city":"Detroit","state":"Michigan","zip":"48236","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Research Site","city":"Omaha","state":"Nebraska","zip":"68114","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Research Site","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Research Site","city":"Syracuse","state":"New York","zip":"13210","country":"United States","geoPoint":{"lat":43.04812,"lon":-76.14742}},{"facility":"Research Site","city":"The Bronx","state":"New York","zip":"10467","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"Research Site","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Research Site","city":"Goldsboro","state":"North Carolina","zip":"27534","country":"United States","geoPoint":{"lat":35.38488,"lon":-77.99277}},{"facility":"Research Site","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Research Site","city":"QuÃ©bec","state":"Quebec","zip":"G1S 4L8","country":"Canada"},{"facility":"Research Site","city":"Québec","state":"Quebec","zip":"G1S 4L8","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"Research Site","city":"Limoges","zip":"87042","country":"France","geoPoint":{"lat":45.83362,"lon":1.24759}},{"facility":"Research Site","city":"Montpellier","zip":"34298","country":"France","geoPoint":{"lat":43.61093,"lon":3.87635}},{"facility":"Research Site","city":"Nantes","zip":"44035","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"Research Site","city":"Villejuif","zip":"94805","country":"France","geoPoint":{"lat":48.7939,"lon":2.35992}},{"facility":"Research Site","city":"Bologna","zip":"40138","country":"Italy","geoPoint":{"lat":44.49381,"lon":11.33875}},{"facility":"Research Site","city":"Florence","zip":"50139","country":"Italy","geoPoint":{"lat":43.77925,"lon":11.24626}},{"facility":"Research Site","city":"Milan","zip":"20162","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Research Site","city":"Padua","zip":"35128","country":"Italy","geoPoint":{"lat":45.40797,"lon":11.88586}},{"facility":"Research Site","city":"Roma","zip":"00128","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"facility":"Research Site","city":"Warsaw","zip":"01-809","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}}]},"referencesModule":{"references":[{"pmid":"23990665","type":"DERIVED","citation":"Hu MI, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Ying W, Jain RK. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst. 2013 Sep 18;105(18):1417-20. doi: 10.1093/jnci/djt225. Epub 2013 Aug 29."}],"seeAlsoLinks":[{"label":"AmgenTrials clinical trials website","url":"http://www.amgentrials.com"}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"First patient was enrolled on 16 November 2009 and the last patient enrolled on 02 July 2012. Data are reported as of the primary analysis cut-off date of 13 September 2012.","groups":[{"id":"FG000","title":"Denosumab","description":"Participants received denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study Days 8 and 15."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"33"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"33"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"10"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"8"}]},{"type":"Disease Progression","reasons":[{"groupId":"FG000","numSubjects":"5"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"4"}]},{"type":"Requirement for alternative therapy","reasons":[{"groupId":"FG000","numSubjects":"3"}]},{"type":"Ongoing in study","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Denosumab","description":"Participants received denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study Days 8 and 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"33"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60.3","spread":"14.8"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"12"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"21"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"White or Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"23"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}]},{"title":"Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","description":"Scale used to assess how a patient's disease is progressing, how the disease affects the daily living abilities of the patient: 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, ambulatory, able to carry out work of a light nature; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about \\> 50% of waking hours; 3 = Capable of only limited self care, confined to a bed or chair \\> 50% of waking hours; 4 = Completely disabled, confined to bed or chair; 5 = Dead.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"0","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"1","categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}]},{"title":"2","categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}]},{"title":"3","categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}]},{"title":"4","categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}]}]},{"title":"Primary Tumor Type","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Bladder","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Breast","categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}]},{"title":"Head and neck","categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}]},{"title":"Liver","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Neuroendocrine/carcinoid","categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}]},{"title":"Non-hodgkin's","categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}]},{"title":"Non-small cell lung cancer","categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}]},{"title":"Ovarian","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Renal","categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}]},{"title":"Small cell lung cancer","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Soft tissue sarcoma","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Unknown (primary tumor)","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Multiple myeloma","categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}]},{"title":"Chronic lymphocytic leukemia","categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}]},{"title":"IGG kappa multiple myeloma","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Myeloma","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]}]},{"title":"Time from initial cancer diagnosis to enrollment","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"months","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56.9","spread":"68.8"}]}]}]},{"title":"Presence of metastatic disease at enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"BG000","value":"30"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}]}]},{"title":"Presence of bone metastatic disease at enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}]}]},{"title":"Baseline Hypercalcemia of Malignancy (HCM) Symptoms","description":"Participants may have had more than one symptom","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Fatigue","categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}]},{"title":"Anorexia","categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}]},{"title":"Nausea","categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}]},{"title":"Depressed level of consciousness","categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}]},{"title":"Vomiting","categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}]},{"title":"Dry mouth","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Constipation","categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}]},{"title":"Lethargy","categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}]},{"title":"Confusion","categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}]},{"title":"Polyuria","categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}]},{"title":"Abdominal pain","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Decreased mental acuity","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Dyspnea","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"General weakness","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Insomnolence","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Light headedness (dizziness)","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Listlessness/muscle weakness","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Polyuro-polydipsic syndrome","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Psychomotor retardation","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Retching","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Urinary frequency","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Weight loss","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]}]},{"title":"Calcium (corrected)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"mg/dL","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13.89","spread":"1.27"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With a Response Within 10 Days of First Dose of Denosumab","description":"Response is defined as corrected serum calcium (CSC) ≤ 11.5 mg/dL, within 10 days after the first dose of denosumab. For all CSC values, if albumin was \\< 4 g/dL, the following formula was used to calculate CSC: CSC = Total serum calcium \\[mg/dL\\] + (0.8 x (4 - serum albumin \\[g/dL\\]))","populationDescription":"Response Analysis Subset including all participants who received at least 1 dose of denosumab and had a screening CSC (from local lab) \\> 12.5 mg/dL (3.1 mmol/L).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"10 days","groups":[{"id":"OG000","title":"Denosumab","description":"Participants received denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study Days 8 and 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","lowerLimit":"45.1","upperLimit":"79.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Response by Visit","description":"Response is defined as corrected serum calcium (CSC) ≤ 11.5 mg/dL, within 10 days after the first dose of denosumab. For all CSC values, if albumin was \\< 4 g/dL, the following formula was used to calculate CSC: CSC = Total serum calcium \\[mg/dL\\] + (0.8 x (4 - serum albumin \\[g/dL\\]))","populationDescription":"Response Analysis Subset","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 2, 4, 8, 10, 15, 19, 23, 29, 36, 43, 50 and 57","groups":[{"id":"OG000","title":"Denosumab","description":"Participants received denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study Days 8 and 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"classes":[{"title":"By Day 2","categories":[{"measurements":[{"groupId":"OG000","value":"9.1","lowerLimit":"1.9","upperLimit":"24.3"}]}]},{"title":"By Day 4","categories":[{"measurements":[{"groupId":"OG000","value":"24.2","lowerLimit":"11.1","upperLimit":"42.3"}]}]},{"title":"By Day 8","categories":[{"measurements":[{"groupId":"OG000","value":"48.5","lowerLimit":"30.8","upperLimit":"66.5"}]}]},{"title":"By Day 10","categories":[{"measurements":[{"groupId":"OG000","value":"63.6","lowerLimit":"45.1","upperLimit":"79.6"}]}]},{"title":"By Day 15","categories":[{"measurements":[{"groupId":"OG000","value":"63.6","lowerLimit":"45.1","upperLimit":"79.6"}]}]},{"title":"By Day 19","categories":[{"measurements":[{"groupId":"OG000","value":"69.7","lowerLimit":"51.3","upperLimit":"84.4"}]}]},{"title":"By Day 23","categories":[{"measurements":[{"groupId":"OG000","value":"69.7","lowerLimit":"51.3","upperLimit":"84.4"}]}]},{"title":"By Day 29","categories":[{"measurements":[{"groupId":"OG000","value":"69.7","lowerLimit":"51.3","upperLimit":"84.4"}]}]},{"title":"By Day 36","categories":[{"measurements":[{"groupId":"OG000","value":"69.7","lowerLimit":"51.3","upperLimit":"84.4"}]}]},{"title":"By Day 43","categories":[{"measurements":[{"groupId":"OG000","value":"69.7","lowerLimit":"51.3","upperLimit":"84.4"}]}]},{"title":"By Day 50","categories":[{"measurements":[{"groupId":"OG000","value":"69.7","lowerLimit":"51.3","upperLimit":"84.4"}]}]},{"title":"By Day 57","categories":[{"measurements":[{"groupId":"OG000","value":"69.7","lowerLimit":"51.3","upperLimit":"84.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Complete Response by Visit","description":"Response is defined as corrected serum calcium (CSC) ≤ 10.8 mg/dL (2.7 mmol/L). For all CSC values, if albumin was \\< 4 g/dL, the following formula was used to calculate CSC: CSC = Total serum calcium \\[mg/dL\\] + (0.8 x (4 - serum albumin \\[g/dL\\])).","populationDescription":"Response Analysis Subset","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Days 2, 4, 8, 10, 15, 19, 23, 29, 36, 43, 50 and 57","groups":[{"id":"OG000","title":"Denosumab","description":"Participants received denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study Days 8 and 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"classes":[{"title":"By Day 2","categories":[{"measurements":[{"groupId":"OG000","value":"3.0","lowerLimit":"0.1","upperLimit":"15.8"}]}]},{"title":"By Day 4","categories":[{"measurements":[{"groupId":"OG000","value":"15.2","lowerLimit":"5.1","upperLimit":"31.9"}]}]},{"title":"By Day 8","categories":[{"measurements":[{"groupId":"OG000","value":"27.3","lowerLimit":"13.3","upperLimit":"45.5"}]}]},{"title":"By Day 10","categories":[{"measurements":[{"groupId":"OG000","value":"36.4","lowerLimit":"20.4","upperLimit":"54.9"}]}]},{"title":"By Day 15","categories":[{"measurements":[{"groupId":"OG000","value":"45.5","lowerLimit":"28.1","upperLimit":"63.6"}]}]},{"title":"By Day 19","categories":[{"measurements":[{"groupId":"OG000","value":"45.5","lowerLimit":"28.1","upperLimit":"63.6"}]}]},{"title":"By Day 23","categories":[{"measurements":[{"groupId":"OG000","value":"51.5","lowerLimit":"33.5","upperLimit":"69.2"}]}]},{"title":"By Day 29","categories":[{"measurements":[{"groupId":"OG000","value":"51.5","lowerLimit":"33.5","upperLimit":"69.2"}]}]},{"title":"By Day 36","categories":[{"measurements":[{"groupId":"OG000","value":"60.6","lowerLimit":"42.1","upperLimit":"77.1"}]}]},{"title":"By Day 43","categories":[{"measurements":[{"groupId":"OG000","value":"63.6","lowerLimit":"45.1","upperLimit":"79.6"}]}]},{"title":"By Day 50","categories":[{"measurements":[{"groupId":"OG000","value":"63.6","lowerLimit":"45.1","upperLimit":"79.6"}]}]},{"title":"By Day 57","categories":[{"measurements":[{"groupId":"OG000","value":"63.6","lowerLimit":"45.1","upperLimit":"79.6"}]}]}]},{"type":"SECONDARY","title":"Time to Response","description":"Time to Response was defined as the time period from study Day 1 to the first time post-baseline corrected serum calcium (CSC) ≤ 11.5 mg/dL. Participants were censored on the last CSC assessment day if no response was observed. If there was no post-baseline CSC assessment, time to response was censored on study Day 1.\n\nTime to response was analyzed using Kaplan-Meier methods.","populationDescription":"Response Analysis Subset","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.","groups":[{"id":"OG000","title":"Denosumab","description":"Participants received denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study Days 8 and 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","lowerLimit":"5.00","upperLimit":"19.00"}]}]}]},{"type":"SECONDARY","title":"Time to Complete Response","description":"Time to complete response was defined as the time period from study Day 1 to the first time post-baseline corrected serum calcium (CSC) was ≤ 10.8 mg/dL (2.7 mmol/L). Participants were censored on the last CSC assessment day if no complete response was observed. If there was no post-baseline CSC assessment, time to complete response was censored on study Day 1. Time to complete response was analyzed using Kaplan-Meier methods.","populationDescription":"Response Analysis Subset","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.","groups":[{"id":"OG000","title":"Denosumab","description":"Participants received denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study Days 8 and 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","lowerLimit":"11.00","upperLimit":"43.00"}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"Duration of response is defined as the number of days from the first day of corrected serum calcium ≤ 11.5 mg/dL (2.9 millimoles/L) to the last day of corrected serum calcium ≤ 11.5 mg/dL. Participants were censored on the last CSC assessment day if their CSC level never reached \\> 11.5 mg/dL after the first response. If a participant had no CSC assessment after the first response, duration of response was set to zero and censored. Duration of response was summarized for participants who achieved a response using the Kaplan-Meier method.","populationDescription":"Participants with a response in the Response Analysis Subset","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.","groups":[{"id":"OG000","title":"Denosumab","description":"Participants received denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study Days 8 and 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104.0","lowerLimit":"9.00","upperLimit":"NA","comment":"Not estimable due to the low number of events"}]}]}]},{"type":"SECONDARY","title":"Duration of Complete Response","description":"Duration of complete response is defined as the number of days from the first day of of corrected serum calcium ≤ 10.8 mg/dL (2.7 millimoles/L) to the last day of corrected serum calcium ≤ 10.8 mg/dL. Participants were censored on the last CSC assessment day if their CSC level never reached \\> 10.8 mg/dL after the complete response. If a participant had no CSC assessment after the complete response, duration of complete response was set to zero and censored. Duration of complete response was summarized for participants who achieved a complete response using the Kaplan-Meier method.","populationDescription":"Participants with a complete response in the Response Analysis Subset","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.","groups":[{"id":"OG000","title":"Denosumab","description":"Participants received denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study Days 8 and 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.0","lowerLimit":"1.00","upperLimit":"134.00"}]}]}]},{"type":"SECONDARY","title":"Time to Relapse/Nonresponse of Hypercalcemia of Malignancy","description":"Time to relapse/nonresponse was defined as the number of days from study Day 1 until the last day of CSC ≤ 11.5 mg/dL for all particiipants with relapse after the first response. Participants were censored on the last CSC assessment day if their CSC level never reached \\> 11.5 mg/dL after first response. For participants who never achieved response, time to relapse/nonresponse was set to zero. Otherwise, if there was no post-baseline CSC assessment, time to relapse/nonresponse was censored on study Day 1. Time to relapse/nonresponse was estimated using the Kaplan-Meier method.","populationDescription":"Response Analysis Subset","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.","groups":[{"id":"OG000","title":"Denosumab","description":"Participants received denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study Days 8 and 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","lowerLimit":"5.00","upperLimit":"114.00"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Corrected Serum Calcium","populationDescription":"Efficacy Analysis Subset included all participants who received at least 1 dose of denosumab. n = Number of participants who had non-missing data at Baseline and the time point of interest.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"mmol/L","timeFrame":"Baseline and Days 2, 4, 8, 10, 15, 19, 23, 29, 36, 43, 50 and 57","groups":[{"id":"OG000","title":"Denosumab","description":"Participants received denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study Days 8 and 15."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"}]}],"classes":[{"title":"Change from Baseline to Day 2 (n = 32)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","lowerLimit":"-0.31","upperLimit":"0.09"}]}]},{"title":"Change from Baseline to Day 4 (n = 32)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","lowerLimit":"-0.44","upperLimit":"-0.14"}]}]},{"title":"Change form Baseline to Day 8 (n = 27)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","lowerLimit":"-0.73","upperLimit":"-0.20"}]}]},{"title":"Change from Baseline to Day 10 (n = 28)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.54","lowerLimit":"-0.77","upperLimit":"-0.25"}]}]},{"title":"Change from Baseline to Day 15 (n = 24)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.51","lowerLimit":"-0.89","upperLimit":"-0.15"}]}]},{"title":"Change from Baseline to Day 19 (n = 22)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.64","lowerLimit":"-0.80","upperLimit":"-0.30"}]}]},{"title":"Change from Baseline to Day 23 (n = 21)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.60","lowerLimit":"-0.85","upperLimit":"-0.40"}]}]},{"title":"Change from Baseline to Day 29 (n = 22)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.53","lowerLimit":"-0.75","upperLimit":"-0.30"}]}]},{"title":"Change from Baseline to Day 36 (n = 20)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.61","lowerLimit":"-0.84","upperLimit":"-0.15"}]}]},{"title":"Change from Baseline to Day 43 (n = 19)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.75","lowerLimit":"-0.98","upperLimit":"-0.10"}]}]},{"title":"Change from Baseline to Day 50 (n = 15)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","lowerLimit":"-1.03","upperLimit":"-0.20"}]}]},{"title":"Change from Baseline to Day 57 (n = 17)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.73","lowerLimit":"-1.03","upperLimit":"-0.25"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Median time on study was 1.8 months.","description":"Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.","eventGroups":[{"id":"EG000","title":"Denosumab 120 mg Q4W","description":"Participants received denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study Days 8 and 15.","seriousNumAffected":29,"seriousNumAtRisk":33,"otherNumAffected":26,"otherNumAtRisk":33}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Hypercalcaemia of malignancy","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Oesophageal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Urine output decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Failure to thrive","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":33}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Bladder cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Breast cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Chronic lymphocytic leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Diffuse large B-cell lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Gastrointestinal stromal tumour","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Head and neck cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Hepatic neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Multiple myeloma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Non-small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Ovarian cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Renal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Renal tubular necrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Acute pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":33}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":33}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":33}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":33}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":33}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":33}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":33}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":33}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":33}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":33}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":33}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":33}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":33}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":33}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":33}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":33}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":33}]},{"term":"Fluid overload","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":33}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":33}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":33}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":33}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":33}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":33}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Depressed level of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":33}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":33}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":33}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":33}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":33}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":33}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":33}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":33}]},{"term":"Palmar-plantar erythrodysaesthesia syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":33}]},{"term":"Rash pruritic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":33}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 15.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":33}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication."},"pointOfContact":{"title":"Study Director","organization":"Amgen Inc.","phone":"866-572-6436"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D001943","term":"Breast Neoplasms"},{"id":"C562390","term":"Humoral Hypercalcemia Of Malignancy"},{"id":"D003110","term":"Colonic Neoplasms"},{"id":"D004701","term":"Endocrine Gland Neoplasms"},{"id":"D006258","term":"Head and Neck Neoplasms"},{"id":"D007680","term":"Kidney Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D008223","term":"Lymphoma"},{"id":"D009362","term":"Neoplasm Metastasis"},{"id":"D009101","term":"Multiple Myeloma"},{"id":"D010282","term":"Parathyroid Neoplasms"},{"id":"D013964","term":"Thyroid Neoplasms"},{"id":"D006689","term":"Hodgkin Disease"},{"id":"D008228","term":"Lymphoma, Non-Hodgkin"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D006934","term":"Hypercalcemia"},{"id":"D009369","term":"Neoplasms"}],"ancestors":[{"id":"D009371","term":"Neoplasms by Site"},{"id":"D001941","term":"Breast Diseases"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D015179","term":"Colorectal Neoplasms"},{"id":"D007414","term":"Intestinal Neoplasms"},{"id":"D005770","term":"Gastrointestinal Neoplasms"},{"id":"D004067","term":"Digestive System Neoplasms"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D005767","term":"Gastrointestinal Diseases"},{"id":"D003108","term":"Colonic Diseases"},{"id":"D007410","term":"Intestinal Diseases"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D014571","term":"Urologic Neoplasms"},{"id":"D014565","term":"Urogenital Neoplasms"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D007674","term":"Kidney Diseases"},{"id":"D014570","term":"Urologic Diseases"},{"id":"D052801","term":"Male Urogenital Diseases"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D009370","term":"Neoplasms by Histologic Type"},{"id":"D008232","term":"Lymphoproliferative Disorders"},{"id":"D008206","term":"Lymphatic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D007160","term":"Immunoproliferative Disorders"},{"id":"D007154","term":"Immune System Diseases"},{"id":"D009385","term":"Neoplastic Processes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"},{"id":"D054219","term":"Neoplasms, Plasma Cell"},{"id":"D020141","term":"Hemostatic Disorders"},{"id":"D014652","term":"Vascular Diseases"},{"id":"D002318","term":"Cardiovascular Diseases"},{"id":"D010265","term":"Paraproteinemias"},{"id":"D001796","term":"Blood Protein Disorders"},{"id":"D006402","term":"Hematologic Diseases"},{"id":"D006474","term":"Hemorrhagic Disorders"},{"id":"D010279","term":"Parathyroid Diseases"},{"id":"D013959","term":"Thyroid Diseases"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D002128","term":"Calcium Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D014883","term":"Water-Electrolyte Imbalance"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069448","term":"Denosumab"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"}]}},"hasResults":true}